As a researcher involved in expanding genomic testing pathways, I’d like to ask about the approach used to evaluate patient understanding and outcomes following mainstreamed genetic testing. While the study highlights positive clinician uptake and implementation feasibility, how was patient comprehension, informed consent quality, or psychosocial impact assessed, if at all? Given that non-genetic specialists delivered pre-test information, and that genomic results can be complex and uncertain, omitting an evaluation of patient understanding risks overlooking a key dimension of responsible implementation. Were there any metrics or follow-ups used to evaluate whether patients felt adequately informed and supported, particularly in cases where variants of uncertain significance were returned?
